DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Janus kinase inhibitor
Janus kinase inhibitor
Ruxolitinib for Symptom Control in Patients with Chronic Lymphocytic Leukaemia: a Single- Group, Phase 2 Trial
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
Switching Between Janus Kinase Inhibitor Upadacitinib and Adalimumab Following Insufficient Response: Efficacy and Safety In
The JAK-STAT Pathway and the JAK Inhibitors
The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever
Cytokine Storm Release Syndrome and the Prospects for Immunotherapy with COVID-19, Part 4: the Role of JAK Inhibition Posted August 27, 2020
Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes In
1 Clinical Significance of Janus Kinase Inhibitor Selectivity
Standards, Perspektiven Und Grenzen Der Konservativen Therapie
JPET#223784 Original Article Title: Topically Administered Janus
Pathogenesis of Crohnps Disease
The Novel JAK Inhibitor CYT387 Suppresses Multiple Signalling Pathways, Prevents Proliferation and Induces Apoptosis in Phenotypically Diverse Myeloma Cells
A Compendium of Tyrosine-Kinase Inhibitors: Powerful and Efficient Drugs Against Cancer Costa, D
S12879-020-05730-Z.Pdf
Downloaded from Chemaxon (Budapest, Hungary)[115,171-183]
Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease Models
The Janus-Kinase Inhibitor Ruxolitinib in SARS-Cov-2 Induced Acute
Top View
The Role of JAK-STAT Signaling Pathway and Its Regulators in The
The Effect of BX795 on Type I, II, III Interferons and Interleukin-4
Prospects of JAK Inhibition in the Framework of Bone Loss
Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: a Mid-2016 Overview
Risk Assessment and Risk Mitigation Review(S)
Microrna-130A Regulates Chondrocyte Proliferation and Alleviates Osteoarthritis Through PTEN/PI3K/Akt Signaling Pathway
Molecular Targets in Arthritis and Recent Trends in Nanotherapy Open Access to Scientific and Medical Research DOI
Production in Innate Immune Cells TLR-Mediated Inflammatory Cytokine the Role of JAK-3 in Regulating
Application of Janus Kinase Inhibitors in Atopic Dermatitis: an Updated Systematic Review and Meta-Analysis of Clinical Trials
Janus Kinase Inhibitor INCB20 Has Antiproliferative and Apoptotic Effects on Human Myeloma Cells in Vitro and in Vivo
An Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis J.A
Oclacitinib (APOQUEL) Is a Novel Janus Kinase Inhibitor with Activity
Bone Marrow Niche Dysregulation in Myeloproliferative Neoplasms Ferrata Storti Foundation
Non-Coding DNA in IBD: from Sequence Variation in Gut: First Published As 10.1136/Gutjnl-2018-317516 on 28 January 2019
Mediated Inflammatory Diseases with Janus Kinase Inhibitors
Variable IPSS DIPSS DIPSS-Plus
Old Drugs for JAK-STAT Pathway Inhibition in COVID-19 Patients
(JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis